These are reviewed studies whose abstracts concern Endometrial Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Endometrial Cancer. Most are early lab, animal, or small human studies, and findings often conflict.
4 studies1 human⚠ Conflicting evidenceMechanism (2)Trial (1)
Tracking 4 published studies of Endometrial Cancer: 1 in humans, 3 reviews/other.
Reported direction across studies: 1 positive, 2 mixed, 1 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether anything works for Endometrial Cancer.
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Medicina (Kaunas, Lithuania) · Jun 2025 · review
endometrial carcinosarcomaendometrial cancercarcinosarcoma of the endometrium
This is a narrative review of endometrial carcinosarcoma (ECS), a rare, aggressive biphasic endometrial cancer. The authors summarize epidemiology, pathology including that ECS arises from epithelial components undergoing epithelial-to-mesenchymal transition, prognosis, molecular characteristics, and current and novel therapeutic approaches, noting a poor prognosis and limited high-quality trial evidence.
Reported effects: proportion_diagnosed_early 50% · proportion_with_metastatic_lymph_nodes 33% · +1 more
Key findings
- ECS is a rare, aggressive biphasic metaplastic carcinoma with a monoclonal origin composed of epithelial and mesenchymal components.
- The tumor originates from epithelial components that undergo epithelial-to-mesenchymal transition.
- Approximately half of patients are diagnosed at early stage and half at advanced stage.
- More than one-third of women present with metastatic lymph nodes and approximately 10% have distant metastases.
- ECS has the worst prognosis among endometrial cancers compared with other high-grade endometrial carcinomas.
- Surgical resection with adjuvant therapy remains the standard of care in most cases.
- Rarity of ECS limits prospective clinical trials and the development of specific management guidelines.
- The review discusses molecular characteristics and new treatment regimens for primary (early and advanced) and recurrent ECS.
Limitations: This article is a review and presents no new primary data.; The rarity of ECS limits the ability to conduct prospective clinical trials and to establish optimal treatment regimens (stated in abstract).; No specific treatment guidelines exist for ECS, reflecting limited high-quality evidence (stated in abstract)..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Meta-analysisTrialReported positiveModerate evidenceTier 4 · clinicaln = 2456
Cancer treatment reviews · Apr 2024 · meta-analysis of randomized controlled trials (first-line ICI + platinum-based chemotherapy vs chemotherapy alone)
advanced endometrial cancerrecurrent endometrial cancerendometrial carcinosarcoma
This meta-analysis pooled five randomized trials (2456 patients) comparing addition of anti-PD-1 or anti-PD-L1 agents to standard platinum-based chemotherapy versus chemotherapy alone as first-line treatment for advanced or recurrent endometrial cancer. Adding immune checkpoint inhibitors improved progression-free survival overall and especially in tumors with deficient mismatch repair (dMMR); in mismatch repair–proficient (pMMR) tumors a statistically significant PFS benefit was reported only with anti-PD-1 agents, not anti-PD-L1 agents. The analysis reports PFS outcomes; the impact on overall survival remains to be clarified.
Reported effects: included patients 2456, n=2456 · pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 · +5 more
Studied with: carboplatin-paclitaxel chemotherapy.
Key findings
- Five randomized trials comprising 2456 patients (1308 received ICIs + chemotherapy and 1148 chemotherapy alone) were included.
- Addition of ICIs to chemotherapy improved PFS in the overall population (pooled HR, 0.63; 95% CI, 0.52–0.76; P < .001).
- In the dMMR subgroup the pooled PFS benefit was larger (pooled HR, 0.34; 95% CI, 0.27–0.44; P < .001).
- In dMMR tumors benefit was seen with both PD-L1 and PD-1 inhibitors (pooled HRs 0.39, 95% CI 0.28–0.55 and 0.34, 95% CI 0.27–0.44, respectively; both P < .001).
- In pMMR patients a statistically significant PFS benefit was observed only with anti-PD-1 agents (anti-PD-1: HR 0.64, 95% CI 0.46–0.90, P = .010) but not with anti-PD-L1 agents (anti-PD-L1: HR 0.87, 95% CI 0.73–1.03, P = .104).
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMechanismMixed resultsLimited evidenceTier 1 · lab
International journal of molecular sciences · Aug 2021 · review
breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma
This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.
Key findings
- High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
- Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
- The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
- The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.
Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..
This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMixed resultsLimited evidenceTier 4 · clinical
Gynecologic oncology · Feb 2021 · contemporary clinical summary and molecular review
This review summarizes recent clinical and molecular findings about uterine carcinosarcoma, a rare aggressive endometrial cancer. It reports that multimodal treatment is commonly used, and that carboplatin/paclitaxel adjuvant chemotherapy improved progression-free survival compared with ifosfamide/paclitaxel in the GOG-261 trial. The review also highlights epithelial-mesenchymal transition as an important process in the tumor’s development and discusses common gene mutations seen in these tumors.
Reported effects: annual percent change 1.7% [1.2–2.2] · median survival 2 mo · +6 more
Studied with: ifosfamide/paclitaxel.
Key findings
- Uterine carcinosarcoma incidence has gradually increased over time.
- Median survival remains less than two years and 5-year overall survival has not changed much over decades.
- Carboplatin/paclitaxel adjuvant chemotherapy improved progression-free survival compared with ifosfamide/paclitaxel, particularly in stages III-IV disease.
- Epithelial-mesenchymal transition appears to play a pivotal role in sarcomatous dedifferentiation.
- Common somatic mutations include TP53, PIK3CA, FBXW7, PTEN, and ARID1A.
Limitations: This is a narrative review, not a new experimental study.; Quantitative results are summarized from prior studies rather than generated directly here.; No detailed methods, patient-level data, or full trial design are provided in the abstract.; Some statements are descriptive and not tied to a single controlled comparison..
Useful overview of clinical outcomes and molecular features in uterine carcinosarcoma, including one chemotherapy comparison and discussion of EMT as a potential target.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed